Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
Revolution Medicines, Inc.
Revolution Medicines, Inc.
Thomas Jefferson University
Revolution Medicines, Inc.
Blueprint Medicines Corporation
Blueprint Medicines Corporation
Erasca, Inc.
Blueprint Medicines Corporation
Revolution Medicines, Inc.
Syndax Pharmaceuticals
Syndax Pharmaceuticals
Syndax Pharmaceuticals
The Methodist Hospital Research Institute
H. Lee Moffitt Cancer Center and Research Institute
VA Office of Research and Development